Advertisement

Topics

Study of Sulphonylurea Synergy With Incretins

2018-10-18 12:55:19 | BioPortfolio

Published on BioPortfolio: 2018-10-18T12:55:19-0400

Clinical Trials [4933 Associated Clinical Trials listed on BioPortfolio]

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood lowering effect and the safety profile of repaglinide given alone compared to gliclazide given a...

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

This study is not being conducted in the United States. Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this s...

Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina

The principle objective of the trial is to compare rosiglitazone to gliclazide in patients with type 2 diabetes mellitus and chronic stable angina to see how the subjects' angina status ch...

Study to Compare the Combination of Gliclazide MR and Basal Insulin Versus Premixed Insulin Monotherapy Treatment

The purpose of this study is to demonstrate if the combination treatment of Gliclazide MR and basal insulin can reduce the dosage of insulin and hypoglycemias compared with pre-mix insulin...

Evaluating the True Magnitude of HYPOglycemic Events After THE Initiation of Sulfonylurea

Gliclazide formulations are known to be associated with a lower incidence of hypoglycaemia than glyburide, a characteristic that could impact the choice of second and third line therapy. H...

PubMed Articles [9279 Associated PubMed Articles listed on BioPortfolio]

Monogenic diabetes mellitus in cystic fibrosis.

We present a non-consanguineous family of three siblings who presented with diabetes mellitus (DM), two of whom had genetically confirmed cystic fibrosis (CF), with one pancreatic-sufficient mutation ...

Effects of liraglutide, metformin, and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial.

To compare the effects of gliclazide, liraglutide, and metformin on body composition in patients with type 2 diabetes mellitus patients with non-alcoholic fatty liver disease.

Diabetes remission and relapse after metabolic surgery.

Obesity and type 2 diabetes mellitus are prevalent all over the world. Obese patients with more visceral fat are more likely to suffer from type 2 diabetes mellitus, hypertension, dyslipidemia and obs...

Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.

To analyze the efficacy and safety of replacing sitagliptin with canagliflozin in patients with type 2 diabetes (T2D) and poor metabolic control despite treatment with sitagliptin in combination with ...

Systematic review assessing the effectiveness of dietary intervention on gut microbiota in adults with type 2 diabetes.

Despite improved understanding of the pathophysiology of type 2 diabetes mellitus, explanations for individual variability in disease progression and response to treatment are incomplete. The gut micr...

Medical and Biotech [MESH] Definitions

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).

A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.

A type of diabetes mellitus that is characterized by severe INSULIN RESISTANCE and LIPODYSTROPHY. The latter may be generalized, partial, acquired, or congenital (LIPODYSTROPHY, CONGENITAL GENERALIZED).

A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by excessive LIPOLYSIS, oxidation of FATTY ACIDS, production of KETONE BODIES, a sweet smell to the breath (KETOSIS;) DEHYDRATION; and depressed consciousness leading to COMA.

More From BioPortfolio on "Study of Sulphonylurea Synergy With Incretins"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial